120 related articles for article (PubMed ID: 21924035)
1. [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma].
Liu Y; Jiang Y; Gao Z; Wang X; Han B; Jiang L
Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):704-9. PubMed ID: 21924035
[TBL] [Abstract][Full Text] [Related]
2. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Shi SB; Hu RH; Qi JL; Tang XY; Tian J; Li R; Chang CX
Med Oncol; 2013; 30(2):550. PubMed ID: 23576138
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients.
Lee DH; Choi CM; Kim SW; Suh C; Lee JS
Med Oncol; 2012 Jun; 29(2):640-3. PubMed ID: 21499804
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
8. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
Lee DH; Lee JS; Kim SW; Rodrigues-Pereira J; Han B; Song XQ; Wang J; Kim HK; Sahoo TP; Digumarti R; Wang X; Altug S; Orlando M
Eur J Cancer; 2013 Oct; 49(15):3111-21. PubMed ID: 23890768
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
Schiller JH; von Pawel J; Schütt P; Ansari RH; Thomas M; Saleh M; McCroskey RD; Pfeifer W; Marsland TA; Kloecker GH; Sebastian M; Pirker R; Kurek R; Beadman C; Socinski MA
J Thorac Oncol; 2010 Dec; 5(12):1977-85. PubMed ID: 20978446
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
[TBL] [Abstract][Full Text] [Related]
15. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Chiappori A; Bepler G; Barlesi F; Soria JC; Reck M; Bearz A; Barata F; Scagliotti G; Park K; Wagle A; Liepa AM; Zhao YD; Chouaki N; Iscoe N; von Pawel J
J Thorac Oncol; 2010 Mar; 5(3):369-75. PubMed ID: 20090562
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI.
Hu RH; Shi SB; Qi JL; Tian J; Tang XY; Liu GF; Chang CX
Med Oncol; 2014 Aug; 31(8):63. PubMed ID: 24958515
[TBL] [Abstract][Full Text] [Related]
19. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
[TBL] [Abstract][Full Text] [Related]
20. [Effects of EGFR-TKIs on sequential pemetrexed
for advanced pulmonary adenocarcinoma].
Wang X; Liu Y; Gao Z; Jiang Y; Han B; Jiang L
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):294-8. PubMed ID: 22613336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
